No results for ‘’
Coral Laboratories Ltd
₹585
(4.23%)
Fri, 18 Sept 2026, 00:21 pm
Health Technology
Pharmaceuticals: Other
24.5KCoral Laboratories Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 8.11 | 6.98 | 9.32 | 2.78 | 4.22 | 6.85 | 4.75 | 3.62 | 3.82 | 8.67 | 13.03 | 15.82 | 17.07 | 11.06 | 4.91 | 8.49 | 10.08 | 12.69 | 8.40 | 10.37 |
| Price to book ratio | 2.21 | 1.93 | 1.14 | 0.37 | 0.67 | 0.86 | 0.70 | 0.50 | 0.59 | 1.40 | 2.30 | 2.36 | 1.83 | 0.99 | 0.30 | 0.84 | 0.58 | 0.53 | 0.75 | 1.25 |
| Price to sales ratio | 1.71 | 1.29 | 0.79 | 0.27 | 0.58 | 0.88 | 0.68 | 0.54 | 0.61 | 1.43 | 2.20 | 2.70 | 2.30 | 1.24 | 0.50 | 1.19 | 1.21 | 1.05 | 1.59 | 2.18 |
| Price to cash flow ratio | 22.99 | 7.46 | 0 | 1.80 | 5.44 | 8.31 | 8.41 | 25.51 | 14.64 | 50.79 | 21.08 | 21.08 | 14.84 | 841.41 | 0 | 36.91 | 8.65 | 6 | 5.76 | 11.90 |
| Enterprise value | 35.13Cr | 46.1Cr | 35.21Cr | 15.05Cr | 22.02Cr | 27.52Cr | 22.95Cr | 17.42Cr | 23.48Cr | 77.73Cr | 153Cr | 248Cr | 203Cr | 91.45Cr | 10.7Cr | 86.33Cr | 37.82Cr | 17.34Cr | 45.54Cr | 147Cr |
| Enterprise value to EBITDA ratio | 6.95 | 6.46 | 7.11 | 2.87 | 3.36 | 4.81 | 3.30 | 2.72 | 2.62 | 7.11 | 11.81 | 10.61 | 13.22 | 7.30 | 1.75 | 5.27 | 4.45 | 4.29 | 2.76 | 5.46 |
| Debt to equity ratio | 0.09 | 0.36 | 0.43 | 0.23 | 0.10 | 0 | 0 | 0.01 | 0 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | 0.05 | 0.05 | 0.04 | 0 | 0 | 0.02 |
| Return on equity % | 0 | 31.54 | 12.95 | 13.98 | 16.93 | 13.28 | 15.85 | 14.76 | 16.72 | 17.46 | 19.18 | 18.17 | 12.40 | 8.88 | 6.22 | 10.74 | 6.18 | 4.15 | 9.50 | 12.76 |
Coral Laboratories Ltd Ratios
The Coral Laboratories Ltd Ratios page provides a complete fundamental analysis of Coral Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Coral Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Coral Laboratories Ltd (NSE: , BSE: 524506) is currently trading at ₹585, with a market capitalization of ₹209Cr. As a major player in the Health technology sector and Pharmaceuticals: other industry, Coral Laboratories Ltd remains a key stock for fundamental analysis using Coral Laboratories Ltd Ratios.
Coral Laboratories Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Coral Laboratories Ltd P/E ratio currently stands at 10.37, making it one of the most tracked metrics in Coral Laboratories Ltd Ratios.
Historically, the Coral Laboratories Ltd P/E ratio has shown strong fluctuations:
- 2024: 10.37
- 2023: 8.40
- 2022: 12.69
- 2021: 10.08
- 2020: 8.49
The rising Coral Laboratories Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Coral Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.25.
Historical P/B trend:
- 2024: 1.25
- 2023: 0.75
- 2022: 0.53
- 2021: 0.58
Coral Laboratories Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Coral Laboratories Ltd P/S ratio currently stands at 2.18, an important part of Coral Laboratories Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 2.18
- 2023: 1.59
- 2022: 1.05
- 2021: 1.21
The rising Coral Laboratories Ltd P/S ratio indicates improved revenue valuation by investors.
Coral Laboratories Ltd Price to Cash Flow Ratio (P/CF)
The Coral Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 11.90.
Historical Coral Laboratories Ltd Price to Cash Flow Ratio:
- 2024: 11.90
- 2023: 5.76
- 2022: 6
- 2021: 8.65
- 2020: 36.91
The rising Coral Laboratories Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Coral Laboratories Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Coral Laboratories Ltd EV currently stands at ₹147Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 147Cr
- 2023: 45.54Cr
- 2022: 17.34Cr
- 2021: 37.82Cr
Coral Laboratories Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Coral Laboratories Ltd EV/EBITDA ratio is currently 5.46, a key metric in Coral Laboratories Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 5.46
- 2023: 2.76
- 2022: 4.29
- 2021: 4.45
Higher Coral Laboratories Ltd EV/EBITDA suggests premium valuation.
Coral Laboratories Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Coral Laboratories Ltd D/E ratio is currently 0.02, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.02
- 2023: 0
- 2022: 0
- 2021: 0.04
Coral Laboratories Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Coral Laboratories Ltd ROE currently stands at 12.76%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 12.76
- 2023: 9.50
- 2022: 4.15
- 2021: 6.18
Coral Laboratories Ltd maintains stable profitability levels.
Coral Laboratories Ltd Ratios Analysis Summary
The Coral Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Coral Laboratories Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Coral Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.